Pharmacological treatment for BPH includes 5-α reductase inhibitors as Finasteride and Dutasteride as a monotherapy or in combination with antimuscarinic drugs, alpha-blockers, 5-phosphodiesterase inhibitor drugs. Androgen receptor inhibitors revealed several adverse events as decreased libido, erectile dysfunction, ejaculatory dysfunction, and gynecomastia. Hence, the emergence of complementary and alternative medications having safety profile—preferably, edible natural products—would be highly desirable. In-silico studies based on Maestro Molecular Modelling platform (version 10.5) by Schrӧdinger, LLC was used to identify the lead molecules. The in-vivo activity studied on rats gave the positive results. The findings based on experiments as antioxidant parameters showed the potential to quench the free radicals. The significant results were also seen in prostatic index and histopathological studies supported the above findings. Based on these data, sesamol and derivative have proven efficacy in protecting against testosterone induced BPH.

BPH 的药物治疗包括 5 -α还原酶抑制剂如非那雄胺和度他雄胺作为单一疗法或与抗毒蕈碱药物、α-受体阻滞剂、5-磷酸二酯酶抑制剂药物联合使用。雄激素受体抑制剂揭示了一些不良事件，如性欲下降、勃起功能障碍、射精功能障碍和男性乳房发育。因此，具有安全性的补充和替代药物的出现——最好是可食用的天然产品——将是非常可取的。Schrӧdinger, LLC 基于 Maestro Molecular Modeling 平台（10.5 版）的计算机研究用于识别先导分子。在大鼠身上研究的体内活性给出了积极的结果。基于作为抗氧化参数的实验的发现显示了抑制自由基的潜力。在前列腺指数中也看到了显着的结果，组织病理学研究支持了上述发现。基于这些数据，芝麻酚及其衍生物已被证明可有效预防睾酮诱导的 BPH。